Inflammatory Bowel Disease (IBD) and Covid-19 Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-07

Study Completion Date

2021-01-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Most of the inflammatory bowel disease (IBD: Crohn's disease and ulcerative colitis) in a tertiary expert Centre are on immunosuppressive and/or biological therapy. Theoretically, these treatments may increase patients' risk of infection, in particular viral infection. Therefore, the current SARS-Cov-2 pandemia, with its unprecedent worldwide morbidity and mortality, may have a negative impact on IBD patients' clinical course. Identifying an increased risk in this particular patients' population as well as the risk/protective factors is of outstanding importance, in order to adapt their treatment and surveillance. As a consequence, our aims were (i) to measure retrospectively the risk of SARS-CoV-2 (proven by biological testing or suspected due to record of potential clinical symptoms of COVID-19 infection) in this patients' cohort (principal objective), (ii) to identify risk or protective factors for SARS-CoV-2 infection in IBD, and (iii) to analyze the outcome of patients in case of suspected or confirmed COVID-19. The results of this study may be important to adjust our surveillance and therapeutic strategy in these patients, in particular if high virus circulation will occur in the future.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Obesity on Response to Therapy and Clinical Outcom in Patients With Inflammatory Bowel Disease

NCT07343726

Inflammatory Bowel Disease (IBD)

NOT_YET_RECRUITING

IDENTIFICATION OF PROGNOSTIC AND PREDICTIVE BIOMARKERS IN INFLAMMATORY BOWEL DISEASE

NCT03809728

Inflammatory Bowel Diseases Crohn Disease Ulcerative Colitis

RECRUITING NA

Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic

NCT04344249

IBD COVID

COMPLETED

Platelet Indices in Inflammatory Bowel Diseases

NCT07320443

Inflammatory Bowel Diseases

NOT_YET_RECRUITING

Role of Bile Acids and Microbiota in Clostridioides Difficile Infection in Ulcerative Colitis

NCT06228352

Ulcerative Colitis

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over the age of 18 years
* IBD patients (Crohn's disease, ulcerative colitis, indeterminate colitis)
* Patient agreeing to participate in the study

Exclusion Criteria

* Patient unable to understand the study protocol or to answer simple anamnestic questions due to language barrier
* Patient under guardianship or trusteeship
* Patient under safeguard of justice

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No